88 results about "PLK1" patented technology

The present invention provides pyrimidinediamine compounds useful for inhibiting kinase activity, including the activity of polo-like kinase 1 (PLK1). Also provided are pharmaceutical compositions comprising these compounds and methods of treating diseases associated with kinase activity, in particular enhanced PLK1 catalytic activity, such as diseases associated with abnormal cell proliferation, including neoplastic disorders.

The invention relates to the field of medicinal chemistry, and in particular relates to 2-phenylaminopurine compounds, a preparation method for the compounds, a medicinal composition containing the compounds, and medical applications for the compounds, and in particular an application for the compounds as Polo-like kinase 1 inhibitors.

A genetic biomarker panel is provided for prognosing late onset ER+ breast cancer relapse, in a breast cancer survivor patient. Kits are also provided for measuring levels or the presence of an identified panel of genetic biomarkers. Methods are also provided for identifying a breast cancer survivor patient at a relatively high risk of suffering a breast cancer relapse within 8 years of diagnosis, and therefore suitable for treatment with an aggressive chemotherapeutic regimen. The method may also be used for identifying a breast cancer survivor patient not at high risk of suffering a breast cancer relapse within 8 years of diagnosis, and thus not suitable for treatment with an aggressive chemotherapeutic regimen. The genetic biomarker panel includes an oligonucleotide / nucleic acid sequence specific for the following genes: MKI67, SPAG5, ESPL1, PLK1, or a genetic panel for MKI67, SPAG5, ESPL1, PLK1 and PGR.

The invention relates to an anti-tumor engineering exosome, a preparation method and application. The anti-tumor engineering exosome comprises an exosome body, wherein an anti-tumor nucleic acid medicine and a photosensitizer are coated in the exosome body. Compared with a natural exosome Nex, the engineering exosome Nex @ siRNA / Ce6 has the following characteristics that 1, tumor cells are killed in a targeted way, and no killing effect is achieved on normal cells; 2, the tumor cell apoptosis is promoted through silencing PLK1 genes; the mouse immune system is activated through inhibiting the PD-L1 expression; and 3, the photosensitizer Ce6 in the engineering exosome generates active oxygen under the illumination; the targeted killing of the tumor cells is promoted through the photodynamic effect generated under the illumination; the active oxygen has the effect of damaging the endosome membrane; the siRNA is promoted to escape into the cytoplasm from the endosome; the gene inhibition effect of the cancer cells is improved; the active oxygen can also promote the M2 type macrophage to turn to the M1 type macrophage; and the anti-tumor effect is synergistically enhanced.

The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.

Compounds that inhibit Plk1, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.